Growth Metrics

Neogenomics (NEO) Assets (2016 - 2026)

Neogenomics filings provide 17 years of Assets readings, the most recent being $1.3 billion for Q1 2026.

  • On a quarterly basis, Assets fell 15.92% to $1.3 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.3 billion, a 15.92% decrease, with the full-year FY2025 number at $1.4 billion, down 16.98% from a year prior.
  • Assets hit $1.3 billion in Q1 2026 for Neogenomics, down from $1.4 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.8 billion in Q1 2022 to a low of $1.3 billion in Q1 2026.
  • Median Assets over the past 5 years was $1.6 billion (2024), compared with a mean of $1.6 billion.
  • Biggest five-year swings in Assets: increased 22.43% in 2022 and later fell 16.98% in 2025.
  • Neogenomics' Assets stood at $1.7 billion in 2022, then decreased by 3.38% to $1.7 billion in 2023, then dropped by 2.57% to $1.6 billion in 2024, then fell by 16.98% to $1.4 billion in 2025, then decreased by 0.98% to $1.3 billion in 2026.
  • The last three reported values for Assets were $1.3 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.4 billion (Q3 2025) per Business Quant data.